Nature Reviews Rheumatology, Published online: 13 November 2026; doi:10.1038/s41584-026-01455-6 Treatment non-response in spondyloarthritis is heterogeneous rather than a single phenomenon. This Review proposes a framework that distinguishes primary, secondary, divergent non-response and paradoxical reaction, and highlights how separating true from apparent treatment failure could inform more precise therapeutic strategies.
Olivier Fakih, Francesco Ciccia, Denis Poddubnyy, Georg Schett, Stefan Siebert, Nelly Ziade et al. Decoding treatment non-response in spondyloarthritis. // Nature Reviews Rheumatology. – 2026. – DOI: 10.1038/s41584-026-01455-6. – URL: https://www.nature.com/articles/s41584-026-01455-6
Olivier Fakih, Francesco Ciccia, Denis Poddubnyy, Georg Schett, Stefan Siebert, Nelly Ziade, & Helena Marzo-Ortega (2026). Decoding treatment non-response in spondyloarthritis. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-026-01455-6
Olivier Fakih, et al. “Decoding treatment non-response in spondyloarthritis.” Nature Reviews Rheumatology, 2026. doi:10.1038/s41584-026-01455-6.
@article{Fakih2026,
title = {Decoding treatment non-response in spondyloarthritis},
author = {Fakih, Olivier and Ciccia, Francesco and Poddubnyy, Denis and Schett, Georg and Siebert, Stefan and Ziade, Nelly and Marzo-Ortega, Helena},
journal = {Nature Reviews Rheumatology},
year = {2026},
doi = {10.1038/s41584-026-01455-6},
url = {https://www.nature.com/articles/s41584-026-01455-6}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...